A one year, multicenter, open-label, single arm, pilot study of the renal safety of everolimus in addition to cyclosporine microemulsion in cardiac transplant recipients.
Latest Information Update: 14 Mar 2015
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin
- Indications Heart transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 08 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 01 Nov 2011 Planned end date (Jul 2006) added as reported by ClinicalTrials.gov.
- 13 Dec 2005 New trial record.